top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

12/03/2026


























Aminex Therapeutics' AMXT 1501 received the FDA ODD for Glioma (Ref)


The US FDA granted the orphan drug designation to Aminex Therapeutics' AMXT 1501 (polyamine transport inhibitor) + difluoromethylornithine for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG).


  • The Beat Childhood Cancer Research Consortium at Penn State College of Medicine, in partnership with Aminex, is actively enrolling patients in a national Phase 1/2 NCT06465199 trial of AMXT 1501 + DFMO in pediatric patients with DIPG, neuroblastoma, sarcomas and other high-risk childhood cancers




Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page